iberdomide (CC-220)

News alerts, weekly reports and conference planners

Company:

BMS

Drug class:

CRL4-CRBN E3 ubiquitin ligase modulator

Related drugs:

‹

›

CRBN underexpression	Multiple Myeloma	CRBN underexpression	Multiple Myeloma	CC-220 Sensitive: C3 – Early Trials CC-220 Sensitive : C3	CC-220 Sensitive: C3 – Early Trials CC-220 Sensitive : C3
TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	CC-93269 + CC-220 Sensitive: D – Preclinical CC-93269 + CC-220 Sensitive : D	CC-93269 + CC-220 Sensitive: D – Preclinical CC-93269 + CC-220 Sensitive : D

Associations
(2)